Hypertension, Vol 6, 229-235, Copyright © 1984 by American Heart Association
M Yasujima, K Abe, M Tanno, Y Kasai, J Tajima, M Seino, S Chiba, K Sato, T Goto and K Omata
To study the hypotensive mechanism of the new oral converting-enzyme
inhibitor, MK-421, we evaluated the antihypertensive effect of MK-421 in
rats with hypertension induced by chronic administration of norepinephrine
(NE) or vasopressin and measured urinary kallikrein and kinin excretions as
indices of the renal kallikrein-kinin system. When 6 mg/kg/day of MK-421
was administered simultaneously with 1.8 mg/kg/day of NE, the systolic
blood pressure of conscious rats rose on Day 1 to only 122.6 +/- 3.4 mm Hg
compared with the rise to 146.3 +/- 1.6 mm Hg when NE alone was infused (p
less than 0.001). Similarly, when the same dose of MK-421 was administered
simultaneously with 7.2 U/kg/day of vasopressin, the systolic blood
pressure of conscious rats rose on Day 1 to only 117.4 +/- 3.8 mm Hg
compared with the rise to 141.6 +/- 3.4 mm Hg when vasopressin alone was
infused (p less than 0.01). The antihypertensive effect of MK-421 was
sustained for 6 days in rats infused with NE or vasopressin. Infusion of NE
alone resulted in a small but significant increase in urinary kallikrein
excretion and no change in urinary kinin excretion. The combined
administration of NE with MK-421 induced additional increases in urinary
kallikrein and kinin excretions. Vasopressin alone resulted in marked
decreases in urinary kallikrein and kinin excretions. The combined
administration of vasopressin with MK-421 induced no additional changes in
urinary kallikrein and kinin excretion. These results indicate that the
hypotensive effect of MK-421 may depend on a reduced sensitivity of the
peripheral arteries to vasoconstrictor substances.(ABSTRACT TRUNCATED AT
250 WORDS)
ARTICLES
Antihypertensive effect of MK-421 in rats. Role of the renal kallikrein- kinin system
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1984 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |